FDA Grades Itself Highly In Reports On Safety Of Imported Products And Marketed Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
As Congressional markups of user fee bills looms, the agency describes actions it has taken to protect the international supply chain in its Global Engagement report; another report notes the REMS and drug safety studies it has mandated under its postmarket drug safety program.